Latest news with #BLCO
Yahoo
4 days ago
- Business
- Yahoo
1 Stock Under $50 to Target This Week and 2 We Ignore
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market. This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. That said, here is one stock under $50 with massive upside potential and two that could be down big. Two Stocks Under $50 to Sell: Bausch + Lomb (BLCO) Share Price: $14.11 With a nearly 170-year history dedicated to vision care and eye health innovation, Bausch + Lomb (NYSE:BLCO) develops and manufactures a comprehensive range of eye health products including contact lenses, pharmaceuticals, surgical devices, and consumer eye care solutions. Why Do We Think Twice About BLCO? 7.2% annual revenue growth over the last five years was slower than its healthcare peers 23.9 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution Bausch + Lomb is trading at $14.11 per share, or 16.7x forward P/E. Dive into our free research report to see why there are better opportunities than BLCO. Westamerica Bancorporation (WABC) Share Price: $47.38 Founded in 1884 and serving communities from Mendocino County in the north to Kern County in the south, Westamerica Bancorporation (NASDAQ:WABC) provides banking services to individuals and small businesses throughout Northern and Central California. Why Does WABC Worry Us? Annual net interest income growth of 6.5% over the last five years was below our standards for the bank sector Net interest income is projected to tank by 8.9% over the next 12 months as demand evaporates Overall productivity is expected to fall over the next year as Wall Street thinks its potential sales declines will be accompanied by a 2.8 percentage point degradation in its efficiency ratio Westamerica Bancorporation's stock price of $47.38 implies a valuation ratio of 1.3x forward P/B. If you're considering WABC for your portfolio, see our FREE research report to learn more. One Stock Under $50 to Buy: Amalgamated Financial (AMAL) Share Price: $27.53 Founded in 1923 by labor unions seeking a financial institution aligned with worker values, Amalgamated Financial (NASDAQGM:AMAL) operates a values-oriented bank that provides commercial banking, trust services, and investment management to socially responsible organizations and individuals. Why Will AMAL Beat the Market? 10% annual net interest income growth over the last five years surpassed the sector average as its products resonated with borrowers Incremental sales significantly boosted profitability as its annual earnings per share growth of 8% over the last two years outstripped its revenue performance Annual tangible book value per share growth of 20.4% over the last two years was superb and indicates its capital strength increased during this cycle At $27.53 per share, Amalgamated Financial trades at 1x forward P/B. Is now the right time to buy? Find out in our full research report, it's free. High-Quality Stocks for All Market Conditions Donald Trump's April 2024 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don't miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Globe and Mail
02-08-2025
- Business
- Globe and Mail
Stocks in play: Bausch + Lomb Corporation
Today announced its second-quarter 2025 financial results. Revenue of $1.278 Billion. GAAP Net Loss of $62 Million. Bausch + Lomb Corporation shares are trading down $0.43 at $19.74.
National Post
30-06-2025
- Business
- National Post
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
Article content Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Article content Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its innovative product pipeline. Additional details will follow closer to the event. Article content Article content Second-Quarter Conference Call Details Article content About Bausch + Lomb Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit Article content , Article content Instagram Article content , Article content LinkedIn Article content , Article content X Article content and Article content YouTube Article content . Article content © 2025 Bausch + Lomb. Article content Article content Article content Article content Contacts Article content Media Contact: Article content Chris Clark Article content Article content Article content Article content Article content Article content
Business Wire
20-06-2025
- Business
- Business Wire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding BLCO should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
National Post
18-06-2025
- Business
- National Post
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO) ('Bausch + Lomb' or the 'company'), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the 'Issuers'), have priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 ('Notes'). The size of the offering was increased from the previously announced €600 million aggregate principal amount of Notes. The Notes will be sold to investors at a price of 99.500% of the principal amount thereof. Article content As previously announced, the company is also seeking to partially refinance its credit agreement, whereby the company intends to obtain a $2.325 billion new term B loan facility (the 'New Term B Loan Facility') and a new $800 million revolving credit facility (the 'New Revolving Credit Facility'). The New Term B Loan is expected to accrue interest at a rate of Term SOFR + 4.25% per annum. The allocated size of the New Term B Loan Facility was increased from the previously announced $2.2 billion. The company intends to use the net proceeds from the Notes offering and the New Term B Loan Facility to repay in full the outstanding borrowings under its existing revolving credit facility, to refinance in full its outstanding term A loans due 2027 and term B loans due 2027 and to pay related fees and expenses. Article content The closing of the Notes offering is not contingent upon the closing of the New Term B Loan Facility or the New Revolving Credit Facility. Article content The Notes will be guaranteed by the company and each of the company's subsidiaries (other than the Issuers) that are guarantors under the company's credit agreement and will be secured on a first priority basis by liens on the same assets that secure the obligations under the company's credit agreement and the company's outstanding senior secured notes. Article content Closing of the Notes offering is expected to occur on June 26, 2025, subject to customary closing conditions. Article content The Notes will not be registered under the Securities Act of 1933, as amended ('Securities Act'), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes are being offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws. Article content The New Term B Loan Facility and New Revolving Credit Facility are also expected to close on June 26, 2025; however, there can be no assurances that the company will be able to complete the New Term B Loan Facility and/or New Revolving Credit Facility transactions on the terms described above or at all. Article content This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Article content About Bausch + Lomb Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. Article content Forward-looking Statements Article content This news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, 'forward-looking statements'), including, but not limited to, our refinancing plans and the details thereof, including the Notes offering, the New Term B Loan Facility and the New Revolving Credit Facility, the proposed use of proceeds therefrom and the details thereof, our ability to complete the transactions described in this press release, and the other expected effects thereof. Forward-looking statements may generally be identified by the use of the words 'anticipates,' 'seeks,' 'expects,' 'plans,' 'should,' 'could,' 'would,' 'may,' 'will,' 'believes,' 'potential,' 'pending' or 'proposed' and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators (including the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and its most recent quarterly filings). In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including the assumption that the risks and uncertainties discussed in such filings will not cause actual results or events to differ materially from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. Article content Article content Article content Article content Contacts Article content Media Contacts Article content : Article content Article content T.J. Crawford Article content Article content Article content Article content (908) 705-2851 Article content Investor Contacts Article content : Article content Article content George Gadkowski Article content Article content Article content Article content
